Chimeric antigen receptor (CAR)-T-cell therapy appears to be a promising treatment for B-cell and non-Hodgkin's lymphoma. CAR-T therapy effectiveness in the general population of patients may differ from effectiveness demonstrated in trials.
Higher rates of colorectal cancer incidence among black patients are primarily driven by lower rates of colorectal cancer screening. Our findings highlight the need to increase black patients' access to quality screening to reduce colorectal cancer incidence and mortality.
Screenings for breast cancer and colon cancer dropped dramatically during the early months of the coronavirus pandemic, but use of the procedures returned to near-normal levels by the end of July 2020.
Opportunities exist to improve hospice care for symptom palliation and training for caregivers when their family members are at home or in an ALF setting. Efforts to improve care for cancer patients in the NH and ALF setting are especially needed.
This study aimed to describe strategies CHCs use to integrate care with specialists and examine whether more strongly integrated CHCs have higher rates of screening for colorectal and cervical cancers and report better communication with specialists.
Cancer is a leading cause of death in the UK. Action is needed now to recruit and train more NHS staff in certain key cancer-related roles if NHS is to meet its ambitions for improving cancer services over the next 10 years.
Several public cord blood banks are struggling financially, and the question remains whether additional allocations of funds to them are justified. This article estimates the social benefits of public cord blood bank inventory net of cord blood banks' operational costs.
We identified five current cancer coverage state laws and interviewed experts on their perceptions of the relevance of the laws and how well they meet the current needs of cancer care given rapid changes in therapies.
A study exploring the feasibility of introducing OBP for new cancer medicines in the NHS, focusing on the kinds of outcomes that patients and their carers consider most important to refer to in this context.
RAND Europe sought to better understand how commissioners of healthcare services and Cancer Alliances make decisions about early diagnosis interventions at a local level, with a particular focus on England and Northern Ireland.
Successes in the early treatment of breast cancer are to be celebrated. But those achievements need not limit the development of further and better treatment for patients. Understanding the disease's wider effects could help bring this about.
The Vitality Age with pre-existing conditions (VAPC) is an extension to VA.3, allowing explicit differentiation between individuals with one or more selected pre-existing conditions that negatively affect their health and life expectancy.
RAND Europe conducted a study on the societal impact of early breast cancer, divided into three interconnected phases. The third phase was a qualitative study assessing the factors affecting access and delivery of treatment for early breast cancer.
RAND Europe conducted a study on the societal impact of early breast cancer. This study was divided into three connected phases. The second phase was a systematic review on non-clinical outcomes of recurrence after treatment of early breast cancer.